New standards of clinical performance
Utilizing patient- and tumor-specific structural variants (SVs) and proprietary dPCR technology, Pathlight overcomes many key limitations of previous methods for early detection and reliable long-term MRD monitoring.
The power of Pathlight in early-stage breast cancer
In a pivotal study published in Clinical Cancer Research (2025)1, Pathlight demonstrated unmatched sensitivity, specificity, and lead time for early breast cancer (EBC) patients.
Among 100 patients with Stage I–III EBC, Pathlight delivered 100% sensitivity, 100% specificity and a 13.7 month lead time, creating unparalleled opportunities for detecting recurrence earlier, when treatment is most likely to be successful.
Pathlight also breaks the 1ppm barrier, enabling the detection of small, early tumors while they’re still treatable.
%
overall baseline ctDNA detection
(94% ER+, 97% HER2+, 96% TNBC)
%
sensitivity for distant recurrence
(17/17)
%
specificity across all timepoints
(61/61)
months median lead time
(up to 5.3 years)
Patient-specific and tumor-informed for more accurate detection and monitoring
Pathlight utilizes whole-genome sequencing of a patient’s tumor specimen to identify candidate structural variants unique to the patient and the tumor. This information is used to generate a personalized, ultra-sensitive multiplex digital PCR (dPCR) assay or “fingerprint,” used to detect the presence or absence of circulating tumor DNA (ctDNA) in blood.
Pathlight’s proprietary algorithm selects SVs that are less susceptible to therapy selection and clonal evolution, and enables more accurate tracking of response to therapy.
Order Pathlight
Setting up your account is easy. Contact our client services team to create your account and start ordering Pathlight for your patients.
References
- Elliott MJ, Howarth K, Main S, et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clin Cancer Res. Published online January 7, 2025. doi:10.1158/1078-0432.CCR-24-3472